Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Deffered Revenue (2016)

Anika Therapeutics has reported Non-Current Deffered Revenue over the past 7 years, most recently at $48000.0 for Q4 2016.

  • Quarterly Non-Current Deffered Revenue fell 27.27% to $48000.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $48000.0 through Dec 2016, down 27.27% year-over-year, with the annual reading at $48000.0 for FY2016, 27.27% down from the prior year.
  • Non-Current Deffered Revenue was $48000.0 for Q4 2016 at Anika Therapeutics, down from $59000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $4.3 million in Q1 2012 and troughed at $48000.0 in Q4 2016.
  • The 5-year median for Non-Current Deffered Revenue is $79940.5 (2015), against an average of $1.1 million.
  • Year-over-year, Non-Current Deffered Revenue crashed 97.21% in 2014 and then soared 30.74% in 2015.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $2.2 million in 2012, then decreased by 4.54% to $2.1 million in 2013, then crashed by 95.04% to $102000.0 in 2014, then crashed by 35.29% to $66000.0 in 2015, then dropped by 27.27% to $48000.0 in 2016.
  • Per Business Quant, the three most recent readings for ANIK's Non-Current Deffered Revenue are $48000.0 (Q4 2016), $59000.0 (Q3 2016), and $56000.0 (Q2 2016).